Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FYVE, RhoGEF and PH domain-containing protein 3 (FGD3)
- Target
- FGD3
- Molecular classification
- Guanine nucleotide exchange factor (GEF), Signal transduction protein, Other (multidomain signaling and scaffolding protein, containing FYVE, RhoGEF, and PH domains)
01
Overview
FYVE, RhoGEF and PH domain-containing protein 3 (FGD3) is a multidomain signaling protein containing FYVE (zinc finger), RhoGEF (guanine nucleotide exchange factor), and PH (pleckstrin homology) domains[1][2][3][6]. It is encoded by the human FGD3 gene and promotes the formation of filopodia—thin, actin-based protrusions involved in cell movement and sensing—by activating the small GTPase CDC42, facilitating the exchange of GDP for GTP[1][2][3][5][9]. Through its activity, FGD3 is a key regulator of actin cytoskeleton organization, cell shape, and motility, making it of therapeutic interest, particularly in diseases involving aberrant cell migration such as cancer[2][8][9]. Although no approved drugs target FGD3 directly, active drug discovery efforts focus on finding modulators that may influence its role in cytoskeletal regulation[2].
- Other names
- Zinc finger FYVE domain-containing protein 5FGD3FYVE, RhoGEF and PH domain containing 3
02
Mechanism of action
Inhibitors may act by blocking the GEF activity toward CDC42, thereby modulating actin cytoskeleton dynamics and cell morphology/motility
03
Biological functions
Actin cytoskeleton organizationFilopodia formationActivation of small GTPase CDC42, facilitating GDP-GTP exchangeCell morphology regulationCell motility
04
Disease associations
Cancer (aberrant actin cytoskeleton regulation implicated in tumor progression; supported by relevance of RhoGEF proteins to cancer biology, though direct evidence for FGD3's disease association is limited in current search results)Other (altered cell migration/invasion may contribute to additional diseases, but specifics not detailed in present sources)
05
Safety considerations
Not directly reported; as a regulator of the actin cytoskeleton and cell motility, potential for adverse effects could include impairments in normal cell function and migration, but these are theoretical in absence of clinical safety data
06
Interacting drugs
None listed in current results; focused libraries of small molecule modulators exist with research interest
07
Biomarkers
None specifically validated or listed in public results; FGD3 may have future potential as a biomarker in cancers or disorders involving the cytoskeleton based on molecular function, but no clinical assays identified
Beyond the preview
Go deeper on FYVE, RhoGEF and PH domain-containing protein 3 (FGD3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FYVE, RhoGEF and PH domain-containing protein 3 (FGD3).